Mark Sulkowski, MD






Site Investigator

  • Vice-chair, Hepatitis TSG
  • Vice-Chair, Steering Committee of Hepatitis TSG (Dec 2014)
  • Member, HBV Cure Working Group of the HEP TSG (Mar 2015)
  • Co-Vice-Chair, NASH Focus Group of the ITSG/HEPTSG (April 2016)
  • Chair ACTG 5329
  • Co-chair ACTG 5334s
  • Investigator, ACTG 5335s


Leadership Committees

Clinical Trials

P1078: A Phase IV Randomized Double-Blind Placebo-Controlled...

P1078 is a Phase IV, randomized, double-blind, placebo-controlled study of HIV-infected pregnant women and the infants born to...

Read More

A5225: Phase I/II Dose-Finding Study of High-Dose...

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...

Read More

A5337: Safety and Efficacy of Sirolimus for HIV Reservoir...

When a person becomes infected with HIV the immune system (the system that helps fight infection) is weakened (partly because...

Read More

A5332: Randomized Trial to Prevent Vascular Events in HIV...

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....

Read More

A5322: Long-Term Follow-up of Older HIV-infected Adults in...

The A5322 protocol is a long-term observational study, with a planned series of analyses of data to be collected from an...

Read More